Company profile: TheraPharm
1.1 - Company Overview
Company description
- Provider of monoclonal antibody-based diagnostic and therapeutic biotechnology solutions in hematology, specializing in research, development, and manufacturing for targeted radiation of hematopoietic malignant and non-malignant diseases and lymphoproliferative diseases, conditioning for allogeneic stem cells, and diagnostics of inflammatory diseases and bone marrow metastases.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to TheraPharm
Allos Therapeutics
HQ: United States
Website
- Description: Provider of anti-cancer therapeutics, developing and commercializing treatments including FOLOTYN, a folate analogue metabolic inhibitor that accumulates in cancer cells to cause cell death. Also offers Causal AI to predict effects of clinical interventions for complex generics development, and Licensing & Pipeline co-development and drug licensing to make medications more accessible.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allos Therapeutics company profile →
ECM Therapeutics
HQ: United States
Website
- Description: Provider of regenerative natural biomaterials, including extracellular matrix hydrogel for tissue regeneration, void filling, and as a drug carrier; matrix bound nanovesicles offering immunomodulation without suppression, administered intravenously or topically; and FDA-approved extracellular matrix-based surgical scaffolds for applications such as hernia repair and breast reconstruction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ECM Therapeutics company profile →
EMcision
HQ: United Kingdom
Website
- Description: Provider of medical devices for gastrointestinal applications, offering the Habib EndoHPB, an endoscopic bipolar RF probe developed to ablate tissue in the gastro-intestinal tract, and the Habib Endoblate, a bipolar RF probe for endoluminal ablation of gastrointestinal tumours.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EMcision company profile →
Enveric Biosciences
HQ: United States
Website
- Description: Provider of patient-first biotechnology solutions developing rigorously tested, novel cannabinoid medicines and mental health drug candidates, including EB-003, a neuroplastogen for severe disorders without inducing hallucinations; EB-002, a synthetic prodrug of psilocin being studied for psychiatric disorders with altered metabolic and pharmacokinetic properties; and Psybrary, an AI-optimized platform and portfolio of new chemical entities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Enveric Biosciences company profile →
Neon Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies focused on neoantigen-targeted approaches to direct the immune system to recognize and attack cancer. Pipeline includes NEO-PV-01, NEO-PTC-01, and NEO-SV-01.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neon Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for TheraPharm
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to TheraPharm
2.2 - Growth funds investing in similar companies to TheraPharm
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for TheraPharm
4.2 - Public trading comparable groups for TheraPharm
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →